| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Director | Common Shares | 1,730,179 | $90,021,213 | $52.03 | 16 Jul 2025 | Indirect |
| Nkarta, Inc. | Director | Stock Option (right to buy) | 46,000 | 05 Jun 2025 | Direct | ||
| Design Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 19,000 | 10 Jun 2025 | Direct | ||
| CRISPR Therapeutics AG | Director | Stock Option (Right to Buy) | 13,000 | 05 Jun 2025 | Direct | ||
| Turning Point Therapeutics, Inc. | Director | Common Stock | 0 | $76.00 | 17 Aug 2022 | Indirect | |
| Turning Point Therapeutics, Inc. | Director | Stock Option (right to buy) | 0 | 17 Aug 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | 16 Jul 2025 | 3 | +$51,499,918 | 4 | Director | 17 Jul 2025, 17:19 |
| DSGN | Design Therapeutics, Inc. | 10 Jun 2025 | 1 | $0 | 4 | Director, 10%+ Owner | 12 Jun 2025, 16:48 |
| NKTX | Nkarta, Inc. | 05 Jun 2025 | 1 | $0 | 4 | Director | 09 Jun 2025, 16:39 |
| CRSP | CRISPR Therapeutics AG | 05 Jun 2025 | 1 | $0 | 4 | Director | 06 Jun 2025, 17:47 |
| DSGN | Design Therapeutics, Inc. | 13 Jun 2024 | 1 | $0 | 4 | Director, 10%+ Owner | 17 Jun 2024, 17:06 |
| NKTX | Nkarta, Inc. | 13 Jun 2024 | 1 | $0 | 4 | Director | 14 Jun 2024, 16:30 |
| CRSP | CRISPR Therapeutics AG | 30 May 2024 | 1 | $0 | 4 | Director | 31 May 2024, 16:50 |
| NKTX | Nkarta, Inc. | 27 Mar 2024 | 2 | +$20,000,000 | 4 | Director | 28 Mar 2024, 16:30 |
| CRSP | CRISPR Therapeutics AG | 27 Feb 2024 | 3 | +$74,999,996 | 4 | Director | 27 Feb 2024, 18:39 |
| CRSP | CRISPR Therapeutics AG | 08 Jun 2023 | 1 | $0 | 4 | Director | 09 Jun 2023, 17:56 |
| NKTX | Nkarta, Inc. | 07 Jun 2023 | 1 | $0 | 4 | Director | 09 Jun 2023, 17:42 |
| DSGN | Design Therapeutics, Inc. | 31 May 2023 | 1 | $0 | 4 | Director, 10%+ Owner | 02 Jun 2023, 16:48 |
| DSGN | Design Therapeutics, Inc. | 16 Dec 2022 | 3 | +$7,574,078 | 4 | Director, 10%+ Owner | 20 Dec 2022, 17:45 |
| /report/000120919122046285-george-simeon-2022-08-17 | Turning Point Therapeutics, Inc. | 17 Aug 2022 | 4 | -$171,278,160 | 4 | Director | 17 Aug 2022, 16:40 |
| DSGN | Design Therapeutics, Inc. | 15 Jun 2022 | 1 | $0 | 4 | Director, 10%+ Owner | 16 Jun 2022, 17:07 |
| CRSP | CRISPR Therapeutics AG | 09 Jun 2022 | 1 | $0 | 4 | Director | 10 Jun 2022, 17:39 |
| NKTX | Nkarta, Inc. | 08 Jun 2022 | 1 | $0 | 4 | Director | 10 Jun 2022, 16:07 |
| NKTX | Nkarta, Inc. | 28 Apr 2022 | 2 | +$19,999,995 | 4 | Director | 29 Apr 2022, 16:27 |
| NKTX | Nkarta, Inc. | 13 Jun 2021 | 1 | $0 | 4 | Director | 15 Jun 2021, 10:29 |
| CRSP | CRISPR Therapeutics AG | 10 Jun 2021 | 1 | $0 | 4 | Director | 14 Jun 2021, 17:37 |
| /report/000120919121038336-george-simeon-2021-06-02 | Turning Point Therapeutics, Inc. | 02 Jun 2021 | 1 | $0 | 4 | Director | 04 Jun 2021, 17:44 |